Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes; to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease; and to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. It is not known if Ozempic® is safe and effective for use in children.
Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Ozempic® may cause serious side effects, including possible thyroid tumors, including cancer. Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Ozempic® and medicines that work like it caused thyroid tumors, including thyroid cancer. It is not known if Ozempic® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use Ozempic® if you or any of your family have ever had MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you are allergic to semaglutide or any of the ingredients in Ozempic®.
Before using Ozempic®, tell your provider if you have or have had problems with your pancreas; a history of diabetic retinopathy; severe stomach problems such as gastroparesis; are scheduled for surgery using anesthesia or deep sedation; or are pregnant, breastfeeding, or plan to become pregnant. You should stop using Ozempic® at least 2 months before you plan to become pregnant. Tell your provider about all medicines you take, including insulin or sulfonylureas.
Serious side effects may include inflammation of the pancreas (pancreatitis); changes in vision; low blood sugar (hypoglycemia); dehydration leading to kidney problems; severe stomach problems; serious allergic reactions; gallbladder problems; and food or liquid getting into the lungs during surgery or procedures using anesthesia or deep sedation. The most common side effects may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity: to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight; and that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep it off. Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy® is safe and effective for use in children under 12 years of age.
Wegovy® may cause possible thyroid tumors, including cancer (MTC). Do not use Wegovy® if you or any of your family have ever had MTC or have MEN 2, or if you have had a serious allergic reaction to semaglutide or any of its ingredients. Before using, tell your provider if you have or have had problems with your pancreas or kidneys; type 2 diabetes and a history of diabetic retinopathy; depression, suicidal thoughts, or mental health issues; are scheduled for surgery with anesthesia or deep sedation; or are pregnant/plan to become pregnant (stop 2 months before) or breastfeeding.
Serious side effects may include pancreatitis; gallbladder problems; increased risk of low blood sugar; kidney problems (kidney failure); severe stomach problems; serious allergic reactions; change in vision in people with type 2 diabetes; increased heart rate; depression or thoughts of suicide; and food/liquid getting into the lungs during procedures using anesthesia or deep sedation. The most common side effects may include nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, upset stomach, dizziness, feeling bloated, belching, low blood sugar (in type 2 diabetes), gas, stomach flu, heartburn, and runny nose or sore throat.
Zepbound® is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep it off; and adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. Do not use Zepbound if you or any of your family have ever had MTC, if you have MEN 2, or if you have had a serious allergic reaction to tirzepatide or any of its ingredients.
May include severe stomach problems; kidney problems (kidney failure); gallbladder problems; pancreatitis; serious allergic reactions; low blood sugar (hypoglycemia); changes in vision in patients with type 2 diabetes; depression or thoughts of suicide; and food/liquid getting into the lungs during procedures using anesthesia or deep sedation.
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. Zepbound is injected under the skin once weekly, at any time of day, rotating the injection site. It is approved as 2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL in single-dose pen or vial. Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Mounjaro® is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes, and is not known to be safe and effective in children under 18.
Mounjaro may cause thyroid tumors, including thyroid cancer. Do not use Mounjaro if you or your family have ever had MTC, if you have MEN 2, or if you are allergic to it or any of its ingredients.
Serious side effects may include pancreatitis, low blood sugar, serious allergic reactions, kidney problems, severe stomach problems, changes in vision, gallbladder problems, and food/liquid getting into the lungs during procedures using anesthesia or deep sedation. The most common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. Mounjaro is a pre-filled single-dose pen available in 2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL. Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Your medical provider may recommend personalized dosages of compounded semaglutide based on a medical review. Compounded drugs are not FDA approved and are not evaluated by the FDA for safety, effectiveness, or quality standards. This document is a summary of product information and does NOT contain all possible information and potential side effects. This is not medical advice and does not substitute advice from your health care provider. Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review.
Compounded semaglutide is an injectable prescription medicine that may help adults and adolescents with obesity and excess weight — who may also have weight-related medical problems — lose weight and keep it off, used with a reduced-calorie diet and increased physical activity, for people with an initial BMI of 27 kg/m² or higher. It should not be used with other semaglutide-containing products or any other GLP-1/GIP receptor agonist medicines. It is not known if it is safe in people who have had pancreatitis, or in children under 18.
In studies with mice and rats, semaglutide caused thyroid tumors, including thyroid cancer. It is not known if compounded semaglutide will cause thyroid tumors or MTC in people. Do not use it if you or any of your family have ever had MTC or if you have MEN 2. Tell your provider about a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
The pre-filled vial is self-administered subcutaneously in the stomach, thigh, or upper arm once a week on the same day. Do not change your dosing or stop without discussing with your provider. Tell your provider about all medications you take (especially diabetes medicines like insulin or sulfonylureas and other GLP-1/GIP medicines), and your full medical history including type 1/2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression, or suicidal thoughts. Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding — do not use during pregnancy or while breastfeeding; discontinue at least 2 months before a planned pregnancy.
The most common side effects are typically mild and usually resolve after the first several weeks: nausea, vomiting, diarrhea, constipation, abdominal pain, upset stomach, distension, reflux, headache, fatigue, dizziness, and injection-site reactions. Serious side effects to monitor include thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury, serious allergic reactions, diabetic retinopathy complications, increased heart rate, and suicidal behavior/ideation. Never share a vial/needle/syringe. Do not take two or more GLP-1/GIP medications at the same time. Failure to disclose your full medical history may result in serious side effects, including death. If you are experiencing a medical emergency, call 911.
Weeks 1–4: 0.25 mg/week · Weeks 5–8: 0.5 mg/week · Weeks 9–12: 1 mg/week · Weeks 13–16: 1.7 mg/week · Weeks 17–20: 2.4 mg/week. Your maintenance dose could be lower than 2.4 mg/week. Oral forms are typically dosed between 5–10 mg daily. Follow the dosing instructions from your provider.
Legal: Compounded semaglutide is not approved by the FDA. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Byetta and Bydureon are registered trademarks of Amylin Pharmaceuticals, Inc.
Your medical provider may recommend personalized dosages of compounded tirzepatide based on a medical review. Compounded drugs are not FDA approved and are not evaluated by the FDA for safety, effectiveness, or quality standards. This is a summary and does NOT contain all possible information and potential side effects. This is not medical advice. Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review.
Compounded tirzepatide is an injectable prescription medicine that may help adults and adolescents with obesity and excess weight lose weight and keep it off, used with a reduced-calorie diet and increased physical activity, for people with an initial BMI of 27 kg/m² or higher. It should not be used with other tirzepatide-containing products or any other GLP-1/GIP receptor agonist medicines. It is not known if it is safe in people who have had pancreatitis, or in children under 18.
In studies with mice and rats, tirzepatide caused thyroid tumors, including thyroid cancer. It is not known if compounded tirzepatide will cause thyroid tumors or MTC in people. Do not use it if you or any of your family have ever had MTC or if you have MEN 2.
The pre-filled vial is self-administered subcutaneously in the stomach, thigh, or upper arm once a week on the same day. Do not change your dosing or stop without discussing with your provider. Tell your provider about all medications (especially diabetes medicines and other GLP-1/GIP medicines) and your full medical history. Do not use during pregnancy or while breastfeeding; discontinue at least 2 months before a planned pregnancy. Failure to fully disclose your medical history may result in serious side effects, including death.
The most common side effects are typically mild and resolve after the first several weeks: nausea, vomiting, diarrhea, constipation, abdominal pain, upset stomach, distension, reflux, headache, fatigue, dizziness, and injection-site reactions. Serious side effects to monitor include thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury, serious allergic reactions, diabetic retinopathy complications, increased heart rate, and suicidal behavior/ideation. Never share a vial/needle/syringe. If you are experiencing a medical emergency, call 911.
Weeks 1–4: 2.5 mg/week · Weeks 5–8: 5 mg/week · Weeks 9–12: 7.5 mg/week · Weeks 13–16: 10 mg/week · Weeks 17–20: 12.5 mg/week · Weeks 21–24: 15 mg/week. Your maintenance dose could be lower than 15 mg/week. Oral forms are typically dosed between 3–6 mg daily; micro-dosing starts at 1.25 mg once or twice weekly (oral typically 1.5 mg daily). Follow the dosing instructions from your provider.
Legal: Compounded tirzepatide is not approved by the FDA. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Byetta and Bydureon are registered trademarks of Amylin Pharmaceuticals, Inc.